Teva Pharmaceutical Industries Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TEVA.TA | JUBLPHARMA.BO | TAK | EMCURE.BO | 1795.TW | IOLCP.NS | |
|---|---|---|---|---|---|---|
| Market cap | 154.07B | 150.00B | 67.28B | 424.98B | 44.76B | 55.50B |
| P/E (TTM) | 99.3 | 42.7 | 300.9 | 38.9 | 11.8 | 27.3 |
| Forward P/E | 47.7 | 18.7 | 39.7 | 27.9 | 7.1 | 17.5 |
| Price/book | 19.3 | 2.1 | 1.4 | 8.0 | 1.9 | 2.9 |
| Dividend yield | — | 0.53% | 2.93% | 0.17% | 1.61% | 0.54% |
| 1-year change | +66.60% | −19.11% | +54.40% | +59.82% | −42.88% | +102.86% |
| Today | +0.23% | +0.79% | +1.49% | +3.02% | +5.66% | +2.89% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All TEVA.TA news ›Teva to cut 61 jobs in Fairfield as it moves manufacturing out of NJ
Teva Pharmaceuticals USA is headquartered in Parsippany. - PROVIDED BY TEVA Teva Pharmaceuticals USA said it will move manufacturing out of New Jersey as early as next year under a broader restructuring effort. Ahead of the change,
Teva swoops for BioXcel neuroscience assets in bankruptcy sale for up to USD 125m ahead of FDA decision
AllSci Teva Pharmaceutical subsidiary Teva Pharmaceuticals International GmbH announced the acquisition of worldwide rights to BXCL501 (dexmedetomidine) sublingual film from BioXcel Therapeutics I
Teva: I Still See Upside After A Massive Rally
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals. Read more on TEVA here. - Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting…
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Over the past 12 months, shares in Teva Pharmaceutical Industries (TEVA +1.50%) have rallied by around 108%. A key factor for Teva, one of the strongest-performing healthcare stocks, is its success in transforming itself primarily into a…
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
The transaction closed following Teva’s selection as the successful bidder, approval by the U.S. Bankruptcy Court and satisfaction of other closing conditions. Teva acquired the assets for $57.5 million upfront and up to $67.5 million in…
Leader Capital Markets Reaffirms Their Buy Rating on Teva (TEVA)
Leader Capital Markets analyst Sabina Levi maintained a Buy rating on Teva yesterday and set a price target of ILA15,350.00. The company’s shares closed yesterday at ILA12,630.00. According to TipRanks, Levi is a 4-star analyst with an…
Teva (TEVA) Gets a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva on October 23 and set a price target of $44.00. The company’s shares closed last Friday at ILA12,320.00. According to TipRanks, Amsellem is a 5-star analyst with an…
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor. Biopharma dealmaking remained active through the third quarter of 2026. DealForma data…
Return on assets % of TAHO Pharmaceuticals Ltd – TWSE:6467
Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research &…
Gross profit of TAHO Pharmaceuticals Ltd – TWSE:6467
Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research &…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- tradingview.com7
- seekingalpha.com4
- gurufocus.com3
- fool.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 47 articles, not a forecast.